The Siglecs are a family of membrane bound lectins (of the immunoglobulin superfamily) that bind sialic acid and mediate cell-cell interactions. Siglec5 (CD170) is a member of the recently-described human…
| Inventor | Institute |
|---|---|
| Paul Crocker | University of Dundee |
| Cat. #: | 151589 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell biology;Immunology |
| Application: | IHC ; ELISA ; FACS ; IHC ; IF ; IP ; Fn ; WB |
| Target: | Siglec5 |
| Reactivity: | Human |
| Clone: | 1A5 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Sialic Acid Binding Ig Like Lectin 5; Obesity-Binding Protein 2; OB-Binding Protein 2; CD33 Antigen-Like 2; SIGLEC-5; CD33L2; OBBP2; Sialic Acid-Binding Immunoglobulin-Like Lectin 5; CD17 Antigen; |
|---|---|
| Product description: | The Siglecs are a family of membrane bound lectins (of the immunoglobulin superfamily) that bind sialic acid and mediate cell-cell interactions. Siglec5 (CD170) is a member of the recently-described human CD33-related siglec subgroup of sialic acid binding Ig-like lectins and is expressed on myeloid cells of the hemopoietic system. Similar to other CD33- related siglecs, Siglec-5 contains two tyrosine based motifs in its cytoplasmic tails implicated in signalling functions. The antibody cross reacts with Siglec14. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Siglec-5-Fc protein, containing entire extracellular region of siglec-5 fused with the Fc region of human IgG1 |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | The Siglecs are a family of membrane bound lectins (of the immunoglobulin superfamily) that bind sialic acid and mediate cell-cell interactions. Siglec5 (CD170) is a member of the recently-described human CD33-related siglec subgroup of sialic acid binding Ig-like lectins and is expressed on myeloid cells of the hemopoietic system. Similar to other CD33- related siglecs, Siglec-5 contains two tyrosine based motifs in its cytoplasmic tails implicated in signalling functions. The antibody cross reacts with Siglec14. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -80° C |
| Shipping conditions: | Dry ice |
| References: |
Angata et al. 2006. FASEB J. 20(12):1964-73. PMID: 17012248. Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates. Nguyen et al. 2006. Proc Natl Acad Sci U S A. 103(20):7765-70. PMID: 16682635. Loss of Siglec expression on T lymphocytes during human evolution. Avril et al. 2005. J Biol Chem. 280(20):19843-51. PMID: 15769739. Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation. Connolly et al. 2002. Br J Haematol. 119(1):221-38. PMID: 12358929 Human Siglec-5: tissue distribution, novel isoforms and domain specificities for sialic acid-dependent ligand interactions. Cornish et al. 1998. Blood. 92(6):2123-32. PMID: 9731071. Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.